WooGene B&G Co., Ltd. announced that it expects to receive KRW 11 billion in funding from Hyundai Asset Management Co., Ltd. and other investors.
May 16, 2016
Share
WooGene B&G Co., Ltd. (KOSDAQ:A018620) announced a private placement of first unregistered unguaranteed unsecured private convertible bonds for gross proceeds of KRW 11,000,000,000 on May 16, 2016. The bonds will mature on May 20, 2020 with lump-sum redemption of principal on maturity date for the bonds, and yield to maturity of 2%. The zero coupon bonds will be convertible into common shares of the company at a rate of 100% and at a fixed conversion price of KRW 7,085 per share for a conversion period starting from May 20, 2017 to April 20, 2020. The transaction will include participation from Hyundai Season II Mezzanine PEF, a fund managed by Hyundai Asset Management Co., Ltd. for KRW 4,500,000,000, Pine Asia Season II Mezzanine PEF for KRW 1,500,000,000, Yeongu Park for KRW 1,500,000,000, and other investors.
WooGene B&G Co., Ltd. is a Korea-based company mainly engaged in the manufacture of veterinary drugs. The Companyâs products include anti-infective, bulk materials, probiotics, enzymes, antiparasitics, hormone preparations, vaccines, aquacultures, anesthetics, teat dips, disinfectants, pet cure drugs, calcium injections, antiphlogistic injections, enhance metabolism injections, diarrhea remedy injections, sedative injections for swine, toxin binders, pigmentation drugs and others. The Company also provides anti-inflammatory enzymes under the brand name SKD, which are used for human beings. The Company distributes its products within domestic market and to overseas markets, including Iran, Vietnam, Philippines, Brazil and others.
WOOGENE B&G CO., LTD 
